Author: Zhou Hui
Producer: Insight IPO
Shanghai Stock Exchange & Shenzhen Stock Exchange
IPO listing
February 19 - February 25,Shanghai Stock ExchangeShenzhen Stock ExchangeNone of the companies are listed.
Adoption of the Listing Committee Review Meeting
February 19 - February 25,Shanghai Stock ExchangeShenzhen Stock ExchangeNone of the companies have ever met.
Submission of listing application
February 19 - February 25,Shanghai Stock ExchangeShenzhen Stock ExchangeNone of the companies submitted listing applications.
Hong Kong Stock Exchange
IPO listing
February 19-February 25, Hong Kong Stock ExchangeNoneThe company goes public.
IPO Offering
February 19-February 25, Hong Kong Stock ExchangeNoneIPO Offering
Passed the listing hearing
From February 19th to February 25th, the Hong Kong Stock Exchange will have it1 homeThe company passed the hearing.
Data**: publicly available information; Chart Making: Insight IPO 1Hongji Group: A Hong Kong-based structural steel engineering contractor, focusing on the construction, fabrication and installation of structural steel for Hong Kong projects**.
Submission of listing application
From February 19th to February 25th, the Hong Kong Stock Exchange will have it2The company submitted an application for listing on the Main Board.
Data**: publicly available information; Chart Making: Insight IPO 1Paige Biotech: A biotechnology company focused on independent research and development of chronic disease innovation**, with a focus on metabolic disorders.
2.Tea Baidao: In terms of retail sales in 2023, Tea Baidao ranks third in China's freshly made tea shop market.
Paige Biotech disclosed its prospectus on February 23
It is planned to land on the main board of the Hong Kong Stock Exchange
On February 23, Paige Biopharma (Suzhou) Co., Ltd. (hereinafter referred to as Paige Bio) submitted a prospectus to the Hong Kong Stock Exchange to be listed on the main board of the IPO, with CICC as its sole sponsor.
Paige Biosciences is a biotechnology company focused on independent research and development of chronic disease innovations**, with a focus on metabolic disorders. It has independently developed one core product and five other product candidates to capture the huge market opportunities for common chronic and metabolic diseases such as type 2 diabetes mellitus (T2DM), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC) and congenital hyperinsulinemia.
Paige Biotech's core product, PB-119, is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist that is mainly used in the first-line development of T2DM and obesity. It has been shown in multiple clinical trials with comprehensive benefits in blood sugar control, cardiovascular health, and good results for weight management. The New Drug Application (NDA) for PB-119 for **T2DM in China was accepted by the NMPA in September 2023.
According to the prospectus, the funds raised in this offering will be used for the commercialization and indication expansion of the core product PB-119, the further development of the main product PB-718, the continuous and planned research and development of other pipeline candidates, business development activities and strengthening the global network, working capital and other general corporate purposes, and the specific amount of funds raised was not disclosed.
In terms of financial data, Paige Biotech currently does not generate main business income, and will generate other income of 2354 from January to September in 2022 and 2023, respectively70,000 yuan, 110650,000 yuan, and the net profit in the same period was -30.6 billion yuan, -22.5 billion yuan.
Tea Baidao disclosed its prospectus on February 23
It is planned to land on the main board of the Hong Kong Stock Exchange
On February 23, Sichuan Baicha Baidao Industrial Co., Ltd. (hereinafter referred to as Chabaidao) submitted a prospectus to the Hong Kong Stock Exchange to be listed on the main board of the IPO, with CICC as its sole sponsor.
According to Frost & Sullivan's report, in terms of retail sales in 2023, Chabaidao ranks third in China's ready-made tea shop market, with a market share of 68%。As of the Latest Practicable Date, there were 7,927 stores in 31 provinces and cities across the country, and the total retail sales of stores reached approximately RMB16.9 billion in 2023.
The Tea Baidao product portfolio includes classic teas that are normally available all year round, as well as seasonal teas and regional teas that are only available for a limited period or in certain regions, and are mainly developed through a franchise model. Under the franchise model, Chabaidao cooperates with qualified franchisees by participating in business planning and site selection, providing in-depth training and providing first-class raw materials, equipment and services. Franchisees mainly focus on the daily operation and maintenance of their stores, on-site staff management and customer service.
According to the prospectus, the funds raised in this issuance will be used to improve the overall operating capacity and strengthen the ** chain; developing digital capabilities, and engaging and training professionals; branding and promotional activities; promoting self-operated coffee brands and building a network of coffee shops across China; streamlining and optimising product development; working capital and for general corporate purposes. The exact amount of funds raised was not disclosed.
In terms of financial data, from 2021 to 2023, Chabaidao will achieve operating income of 364.4 billion yuan, 423.2 billion yuan, 570.4 billion yuan, and the revenue growth in 2022 and 2023 will be respectively. 80%；Adjusted net income was 90 billion yuan, 96.7 billion yuan, 125.8 billion yuan, and the net profit growth in 2022 and 2023 will be respectively. 07%。
Chabaidao submitted a prospectus to the Hong Kong Stock Exchange on August 15, 2023, which is now invalid.
Readers are advised that this article is based on public information or relevant content provided by interviewees, and the author of Insight IPO and article does not guarantee the completeness and accuracy of relevant information. In any event, the content of this article does not constitute investment advice. The market is risky, and investment needs to be cautious! No **, plagiarism without permission!